SCHEMBL10102543

SCHEMBL10102543

CCCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 16/20 0.86
SRC P12931 11/20 0.86
PDGFRB P09619 8/20 0.86
PDGFRA P16234 8/20 0.86
ABL1 P00519 6/20 0.82
MAPK14 Q16539 6/20 0.82
EGFR P00533 5/20 0.82
WEE1 P30291 4/20 0.82
FGFR2 P21802 2/20 0.82
FGFR4 P22455 2/20 0.82
FGFR3 P22607 2/20 0.82
CHEK1 O14757 1/20 0.82
RIPK2 O43353 1/20 0.82
JAK2 O60674 1/20 0.82
PRKD3 O94806 1/20 0.82
MAP4K4 O95819 1/20 0.82
PAK4 O96013 1/20 0.82
NTRK1 P04629 1/20 0.82
LCK P06239 1/20 0.82
FYN P06241 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1335649 0.93 FGFR1 (1.00) FGFR1SRCPDGFRBPDGFRAABL1
SCHEMBL2083345 0.92 FGFR1 (1.00) FGFR1SRCPDGFRBPDGFRAABL1
Pd-0166285 SCHEMBL133914 0.90 FGFR1 (1.00) FGFR1SRCPDGFRBPDGFRAABL1
Pd-0166285 SCHEMBL30250248 0.90 FGFR1 (1.00) FGFR1SRCPDGFRBPDGFRAABL1
Pd-0166285 SCHEMBL15106017 0.90 FGFR1 (0.98) FGFR1SRCPDGFRBPDGFRAABL1
Pd-0166285 SCHEMBL30276696 0.90 FGFR1 (0.98) FGFR1SRCPDGFRBPDGFRAABL1
Pd-0166285 SCHEMBL15923205 0.89 FGFR1 (0.97) FGFR1SRCPDGFRBPDGFRAABL1
Pd-0166285 SCHEMBL29658286 0.89 FGFR1 (0.97) FGFR1SRCPDGFRBPDGFRAABL1
SCHEMBL29750113 0.89 FGFR1 (0.78) FGFR1SRCPDGFRBPDGFRAABL1
SCHEMBL5764000 0.89 FGFR1 (1.00) FGFR1SRCPDGFRBPDGFRAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-01-07 US disclosed
US-9073916-B2 Prodrug forms of kinase inhibitors and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-07-07 US disclosed
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K FGFR1 115/4885SRC 176/4885PDGFRB 694/4885
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K FGFR1 136/4885SRC 194/4885PDGFRB 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.